Skip to main content

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies

We are redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients.

More About Us

Watch the Company Overview

The GRO Platform

The GRO platform expands the amino acid alphabet to overcome the limitations of protein therapeutics currently impeding the treatment of disease

We’re delivering on the long-awaited promise of protein therapeutics by solving the intrinsic limitations of proteins on potency, stability, and function. The GRO platform shortens development timelines and is the only system capable of seamlessly scaling production of NSAA (non-standard amino acid) proteins to meet clinical needs.

LEARN MORE
Solid GRO Bioscience Blue Circle
Gradient Circle
Science Woman
Gradient Circle Overlay

Our Pipeline

Today, we’re focused on our first two families of NSAA chemistries to drive our product pipeline

GRObio is advancing its first two families of NSAA chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side-effects of protein-based therapies.

LEARN MORE
Light Blue Solid Circle
Gradient Background Circle
Elderly Man with grandson
Gradient Circle Overlay

Featured News

September 28, 2022 in Featured News, News

Drug Target Review: Synthetic biology is ready for the therapeutic limelight

After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell,…
Read More
September 7, 2022 in Featured News, Press Releases

GRO Biosciences Announces Addition of Nicole Paulk, PhD, to Scientific Advisory Board

- Nicole Paulk, an expert in gene therapy, joins GRObio’s Scientific Advisory Board (SAB) as It Advances its ProGlyTM Immunomodulation Chemistries into Gene Therapy - BOSTON, September 7, 2022 -…
Read More
February 3, 2022 in Featured News, Press Releases

GRO Biosciences to Present at 2022 BIO CEO & Investor Conference

BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will…
Read More
VIEW ALL NEWS